# TNBC Off-Label Drugs in Treatment Resistance Research Repurposed drugs matter in TNBC resistance research because they can move faster than brand-new compounds. They already have human safety history, established manufacturing, and real-world prescribing experience. That does not make them proven cancer treatments. It does make them worth tracking when the resistance biology is strong. ### In this section * [Why repurposed drugs matter here](#why-repurposed-drugs-matter-here) * [Pitavastatin as a novel Mcl-1 inhibitor](#pitavastatin-as-a-novel-mcl-1-inhibitor) * [Q\&A: Do other statins do the same thing](#qa-do-other-statins-do-the-same-thing) * [Melatonin](#melatonin) * [Metformin](#metformin) * [Aspirin](#aspirin) * [Where to dig next](#where-to-dig-next) * [What this means in practice](#what-this-means-in-practice) * [References](#references) * [Emerging Resistance Strategies](/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research/emerging-resistance-strategies.md) {% hint style="warning" %} This page is educational only. The evidence here is mainly preclinical. Do not start or switch to an off-label drug on the basis of this page without oncology and pharmacy review. {% endhint %} ### Why repurposed drugs matter here Treatment-resistant TNBC often depends on several escape routes at once. These can include **apoptosis evasion**, cancer stem-cell persistence, drug efflux, and bypass survival signalling. Repurposed drugs are interesting when they hit more than one of those routes together. ### Pitavastatin as a novel Mcl-1 inhibitor A notable 2025 paper from Korea University placed **pitavastatin** on the TNBC resistance map. The study reported that pitavastatin directly binds and inhibits **Mcl-1**, an anti-apoptotic protein that is often upregulated in paclitaxel-resistant TNBC. That matters because **Mcl-1** helps resistant tumour cells avoid programmed cell death. By inhibiting **Mcl-1**, pitavastatin was reported to: * increase mitochondrial **ROS** * reduce mitochondrial membrane potential * deplete **ATP** * trigger caspase-mediated apoptosis in resistant cells The same study also linked pitavastatin to broader anti-resistance effects. Reported findings included: * suppression of cancer stem-cell features, including high **ALDH1** activity and **CD44high/CD24low** phenotype * downregulation of **P-glycoprotein**, a major drug-efflux driver * disruption of **AKT/STAT3** survival signalling The combination data was the most striking part. When combined with **paclitaxel**, pitavastatin showed synergistic activity in patient-derived tumour organoids and significantly reduced tumour growth and lung metastasis in animal models, without overt toxicity in those models. > "We report for the first time that pitavastatin is a direct inhibitor of Mcl-1 and targets heterogeneity in TNBC cells via the suppression of CSC-like properties, thereby preventing distant metastasis and counteracting paclitaxel resistance." > > — Prof. Seo, Korea University This makes pitavastatin one of the more credible repurposing leads in paclitaxel-resistant TNBC. It is still not a validated TNBC treatment in people. ### Q\&A: Do other statins do the same thing? Great question. The short answer is **no, not in the same way**. Pitavastatin is the standout statin for this specific mechanism. It is the only statin currently reported to **directly bind Mcl-1** in TNBC. It also has a roughly **12-hour half-life**, which may help sustain the apoptotic signalling needed to reduce **Mcl-1** and increase pro-apoptotic proteins such as **PUMA** and **NOXA**. Other statins have overlapping but not identical activity. #### Statins with related apoptosis or Mcl-1 relevance * **Simvastatin** — reduces **Mcl-1** expression indirectly and activates integrated stress response signalling in some cancer models * **Lovastatin** — also shows indirect **Mcl-1** and integrated stress response effects in haematologic models * **Atorvastatin** — has mitochondrial apoptosis relevance in lymphoma models, but is less studied for direct **Mcl-1** biology * **Fluvastatin** — has apoptosis-inducing activity in some combination settings, including kidney-cancer work #### What all statins share All statins inhibit **HMG-CoA reductase**. That blocks the **mevalonate pathway**, which cancer cells use for survival signalling, membrane biology, and prenylation of proteins such as **Ras** and **Rho**. That shared upstream action may help explain why several statins can sensitise cancer cells to apoptosis. Pitavastatin appears to go further by adding direct **Mcl-1** binding on top of that. {% hint style="info" %} **Practical takeaway** Being on a common statin such as **atorvastatin**, **rosuvastatin**, or **simvastatin** is not the same as the pitavastatin result reported here. They should not be treated as interchangeable for this mechanism. {% endhint %} ### Melatonin **The short version:** **Melatonin** is a naturally produced hormone and a low-cost supplement with a growing TNBC resistance literature. It now has a newly identified 2026 target in the **FAK–PD-L1** axis. #### How it works in TNBC resistance A January 2026 paper in *Frontiers in Oncology* reported that melatonin suppresses **FAK** signalling and lowers **PD-L1** expression in TNBC cells. That matters because **PD-L1** helps resistant tumours hide from immune attack. Reducing it may help unmask the tumour and improve immune surveillance. This makes melatonin especially relevant to **immunotherapy-combination** thinking. The same study also reported reversal of **EMT** markers in **MDA-MB-231** and **MDA-MB-468** cells. Melatonin increased **E-cadherin** and reduced **β-catenin** plus **vimentin**. That pattern fits lower invasiveness and less metastatic potential. A February 2026 study in *Cancer Letters* added a second resistance angle. It reported that melatonin suppresses **glycolysis** and disrupts **DNA repair** in TNBC. That matters because resistant TNBC often depends on metabolic rewiring and better damage repair to survive chemotherapy stress. Earlier work also showed that melatonin can re-sensitise **olaparib-resistant** TNBC cells. Reported effects included less cancer stem-cell renewal and less invasiveness. #### Why melatonin stands out Melatonin is notable because it appears to hit several resistance routes at once: * **EMT reversal** * **immune evasion** through **PD-L1** reduction * **glycolytic pressure** on Warburg-like metabolism * **cancer stem-cell suppression** It is also inexpensive and already widely used. The limit is the same as with many repurposing leads. Most of the strongest evidence is still **preclinical**. Human TNBC trial data remains limited. ### Metformin **The short version:** **Metformin** is one of the best-studied repurposed drugs in oncology. In TNBC, the evidence now includes both mechanistic work and real-world survival signals. #### Survival signal and updated mechanisms An October 2025 report summarising early-stage TNBC data found that **metformin** and **statins** were each associated with better survival when patients were already taking them for metabolic or cardiovascular reasons. That does not prove causation. It does add real-world weight to the repurposing rationale. It also raises the possibility that metformin and statins could be **synergistic**, which matters in the context of the pitavastatin findings above. A 2025 review of metformin-based combination approaches in TNBC helps clarify why the drug keeps resurfacing. The main mechanisms discussed were: * **AMPK activation** with downstream **mTOR suppression** * reduction of the **CD44high/CD24low** cancer stem-cell compartment * immune-microenvironment shifts that may improve checkpoint-inhibitor response Newer 2025 work adds more specificity. One study reported that metformin can target **FGFR4**, a receptor often overexpressed in TNBC, and enhance the effect of **HDAC inhibitors**. Another line of work combined metformin with **hemin** in **BACH1-depleted** TNBC cells. That combination forced a metabolic shift and then suppressed mitochondrial respiration, with tumour-suppression effects in mouse models. #### Where metformin sits right now Metformin is still not standard of care in TNBC. Clinical trials are ongoing. The main reason it remains interesting is that it is relatively low risk, cheap, and mechanistically broad. It looks most plausible as an **adjunctive sensitisation** strategy rather than as a stand-alone anti-cancer treatment. That is especially relevant when metabolic dysfunction is already part of the wider clinical picture. ### Aspirin **Aspirin** deserves its own place in TNBC off-label research because the signal is less about bulk tumour shrinkage and more about **metastatic spread**, **platelet biology**, and **immune evasion**. That makes it especially relevant in **triple-negative** disease, where **TXA2** and platelet-supported metastasis may matter more. The most useful TNBC-linked reading here is the dedicated [Aspirin in breast cancer page](/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/aspirin-evidence-by-cancer-type/breast-cancer.md). That page covers: * the mixed human evidence in breast cancer * the **TXA2** and platelet-metastasis logic that looks especially relevant to TNBC * why aspirin is still investigational, despite credible anti-metastatic biology For the mechanism-first deep dive, see [Aspirin and Thromboxane A2 (TXA2)](/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/anticancer-mechanisms/aspirin-and-thromboxane-a2-txa2.md). ### Where to dig next Several other off-label leads look worth tracking as this page grows. Most of these signals come from a broader [review covering multiple repurposed-drug candidates in TNBC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12653498/), plus a small number of newer single-topic papers. #### Ivermectin and mebendazole Both have preclinical TNBC data tied to proliferation control and cancer stem-cell suppression in the [repurposed-drug review](https://pmc.ncbi.nlm.nih.gov/articles/PMC12653498/). **Ivermectin** is often discussed through **WNT–TCF** signalling. **Mebendazole** is better known for microtubule disruption and broader anti-resistance overlap. For the fuller mebendazole track, see [Mebendazole in Oncology](/myhealingcommunity-docs/off-label-drugs-for-cancer/mebendazole-in-oncology.md). #### Itraconazole and NSAID strategies **Itraconazole** remains relevant because of **Hedgehog**, **VEGF**, and anti-metastatic biology in both the [repurposed-drug review](https://pmc.ncbi.nlm.nih.gov/articles/PMC12653498/) and the TNBC-specific [itraconazole breast-cancer page](/myhealingcommunity-docs/off-label-drugs-for-cancer/itraconazole-in-oncology/itraconazole-evidence-by-cancer-type/breast-cancer.md). **Aspirin**, **indomethacin**, and wider **COX-2** inhibition also deserve attention because **COX-2** overexpression can support immune evasion and metastasis in TNBC, again summarised in the [same review](https://pmc.ncbi.nlm.nih.gov/articles/PMC12653498/). Some preclinical work suggests these agents can increase sensitivity to **paclitaxel** or **doxorubicin**. #### Antidepressants, HORMAD1, and melatonin combinations **Fluoxetine** and **imipramine** are being explored for their effects on multidrug-resistance pumps plus autophagy and apoptosis in the [repurposed-drug review](https://pmc.ncbi.nlm.nih.gov/articles/PMC12653498/). **HORMAD1** is a newer 2026 target worth watching as the literature matures, based on the [March 2026 research summary](https://medicalxpress.com/news/2026-03-triple-negative-breast-cancer-hormad1.html). The **melatonin + immunotherapy** angle also looks like a natural next deep dive because the [FAK–PD-L1 melatonin paper](https://pmc.ncbi.nlm.nih.gov/articles/PMC12964572/) fits directly with **pembrolizumab-era** TNBC logic. ### What this means in practice **Pitavastatin**, **melatonin**, and **metformin** each show a different version of the same pattern. They touch more than one resistance route at once. That is exactly why they keep appearing in TNBC literature. The honest picture is still mixed. **Pitavastatin** has one of the clearest mechanism-first stories. **Melatonin** looks unusually broad for a low-cost adjunct, especially at the immune-evasion and EMT level. **Metformin** has the widest general oncology literature and now some real-world TNBC survival context. None of them are validated TNBC treatments on the basis of the current evidence. They are best understood as **research leads** and possible future combination partners. For the broader **on-the-horizon** side of TNBC resistance research, see [Emerging Resistance Strategies](/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research/emerging-resistance-strategies.md). ### References * [Pitavastatin is a novel Mcl-1 inhibitor that overcomes paclitaxel resistance in triple-negative breast cancer](https://pubmed.ncbi.nlm.nih.gov/41126317/) * [Statins, Mcl-1, and integrated stress response context](https://pmc.ncbi.nlm.nih.gov/articles/PMC10704957/) * [Simvastatin and Mcl-1-related apoptosis context](https://pmc.ncbi.nlm.nih.gov/articles/PMC9688202/) * [Atorvastatin and mitochondrial apoptosis in lymphoma cells](https://academic.oup.com/carcin/article/26/5/883/2390841) * [Fluvastatin combination and apoptosis context](https://pmc.ncbi.nlm.nih.gov/articles/PMC8306262/) * [Mevalonate-pathway and statin repurposing review](https://pmc.ncbi.nlm.nih.gov/articles/PMC11074523/) * [Melatonin inhibits FAK signaling to suppress PD-L1 expression and enhance immune surveillance in TNBC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12964572/) * [Melatonin suppresses glycolysis and disrupts DNA repair in TNBC](https://www.sciencedirect.com/science/article/abs/pii/S0009279726000086) * [Melatonin restores olaparib sensitivity in resistant TNBC models](https://www.sciencedirect.com/science/article/pii/S1043661824003748) * [Statins and Metformin Improve Survival in Patients with Triple-Negative Breast Cancer](https://www.pharmacytimes.com/view/statins-and-metformin-improved-survival-in-patients-with-triple-negative-breast-cancer) * [Metformin-Based Combination Approaches for Triple-Negative Breast Cancer](https://pubmed.ncbi.nlm.nih.gov/40430851/) * [Review covering multiple repurposed-drug candidates in TNBC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12653498/) * [Metformin may modulate the immune microenvironment in TNBC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12653498/) * [Metformin boosts triple-negative breast cancer treatment efficacy through FGFR4-related findings](https://bioengineer.org/metformin-boosts-triple-negative-breast-cancer-treatment-efficacy/) * [Novel repurposed drug combo shows potential in triple-negative breast cancer](https://www.pharmacytimes.com/view/novel-repurposed-drug-combo-shows-potential-in-triple-negative-breast-cancer) * [March 2026 HORMAD1 TNBC research summary](https://medicalxpress.com/news/2026-03-triple-negative-breast-cancer-hormad1.html) {% hint style="info" %} ### In this TNBC resistance series * [Treatment Resistance Research](/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research.md) * [TNBC Natural Compounds in Treatment Resistance Research](/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research/tnbc-natural-compounds-in-treatment-resistance-research.md) * [TNBC Off-Label Drugs in Treatment Resistance Research](/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research/tnbc-off-label-drugs-in-treatment-resistance-research.md) * [Emerging Resistance Strategies](/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research/emerging-resistance-strategies.md) {% endhint %} {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research/tnbc-off-label-drugs-in-treatment-resistance-research.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.